Zusammenfassung
Die Immunhistochemie hat sich zu einem unverzichtbaren Hilfsmittel in der Prostatabiopsiediagnostik entwickelt. Da der Basalzellverlust als ein definierendes Kennzeichen von Malignität angesehen wird, können vor allem Basalzellmarker in der Differenzialdiagnose benigner und maligner Läsionen hilfreich sein. Basalzellzytokeratine und p63 haben daher schon lange einen festen Platz im diagnostischen Repertoire von Uropathologen. Wünschenswert wäre jedoch, diese Negativmarker durch zusätzliche komplementäre Positivmarker zu ergänzen, um die diagnostische Genauigkeit weiter zu erhöhen. Der am weitesten verbreitete Positivmarker ist die α-Methylazyl-CoA-Razemase (AMACR), die im Prostatakarzinom stark aufreguliert ist und sogar mit p63 in einer einzigen Immunfärbung kombiniert werden kann. Dieser Beitrag gibt einen kurzen und kritischen Überblick über gegenwärtige diagnostische Biomarker des Prostatakarzinoms und schlägt darüber hinaus Golgi-Phosphoprotein 2“ (GOLPH2) und „fatty acid synthase“ (FASN) als zusätzliche diagnostische Marker vor.
Abstract
Immunohistochemistry has become an indispensible tool in biopsy diagnostics of prostate tissues. In particular the use of basal cell markers can be useful to differentiate benign and malignant lesions as a lack of basal cells is considered a hallmark of malignancy. Basal cell cytokeratins and p63 have therefore a long standing place in the diagnostic portfolio of most genito-urinary pathologists. However, to complement the use of these negative markers by additional positive immunohistochemistry markers of malignancy would be desirable to further increase diagnostic accuracy. The most widely used positive marker is alpha-methylacyl-CoA racemase (AMACR), which is strongly upregulated in prostate cancer and which can even be combined with p63 in a single immunostaining. This article briefly and critically reviews current diagnostic prostate cancer biomarkers and also suggests golgi phosphoprotein 2 (GOLPH2) and fatty acid synthase (FASN) as additional diagnostic markers.
Literatur
Egevad L, Allsbrook WC Jr, Epstein JI (2006) Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Hum Pathol 37:292–297
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
Dhanasekaran SM, Barrette TR, Ghosh D et al (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826
Kosari F, Munz JM, Savci-Heijink CD et al (2008) Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 14:1734–1743
Latil A, Bieche I, Chene L et al (2003) Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 9:5477–5485
Veltri RW, Isharwal S, Miller MC et al (2008) Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 68:1806–1815
Concato J, Jain D, Li WW et al (2007) Molecular markers and mortality in prostate cancer. BJU Int 100:1259–1263
Kristiansen G, Pilarsky C, Wissmann C et al (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205:359–376
Klotz L (2007) Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol Oncol 25:505–509
Klotz L (2007) Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 4:692–698
Holmberg L, Bill-Axelson A, Garmo H et al (2006) Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 20:845–855
Umbehr M, Kessler TM, Sulser T et al (2008) ProCOC: the prostate cancer outcomes cohort study. BMC Urol 8:9
Bastian PJ, Carter BH, Bjartell A et al (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55:1321–1330
Brawer MK, Peehl DM, Stamey TA, Bostwick DG (1985) Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 45:3663–3667
Epstein JI (2004) Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 17:307–315
Grisanzio C, Signoretti S (2007) p63 in prostate biology and pathology. J Cell Biochem 103:1354–1368
Hedrick L, Epstein JI (1989) Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13:389–396
Signoretti S, Waltregny D, Dilks J et al (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775
Weinstein MH, Signoretti S, Loda M (2002) Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 15:1302–1308
Osunkoya AO, Hansel DE, Sun X et al (2008) Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol 32:461–467
Ali TZ, Epstein JI (2008) False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol 32:1890–1895
Xu J, Stolk JA, Zhang X et al (2000) Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60:1677–1682
Luo J, Zha S, Gage WR et al (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62:2220–2226
Rubin MA, Zhou M, Dhanasekaran SM et al (2002) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662–1670
Farinola MA, Epstein JI (2004) Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol 35:1272–1278
Zhou M, Aydin H, Kanane H, Epstein JI (2004) How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 28:239–243
Jiang Z, Wu CL, Woda BA et al (2004) Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 45:218–225
Murphy AJ, Hughes CA, Lannigan G et al (2007) Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Histopathology 50:243–251
Kristiansen G, Fritzsche FR, Wassermann K et al (2008) GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 99:939–948
Maeda H, Nagata S, Wolfgang CD et al (2004) The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria. J Biol Chem 279:24561–24568
Wolfgang CD, Essand M, Vincent JJ et al (2000) TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci U S A 97:9437–9442
Epstein JI, Carmichael M, Partin AW (1995) OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45:81–86
Shurbaji MS, Kalbfleisch JH, Thurmond TS (1996) Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27:917–921
Swinnen JV, Roskams T, Joniau S et al (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98:19–22
Rossi S, Graner E, Febbo P et al (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707–715
Baron A, Migita T, Tang D, Loda M (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91:47–53
Shah US, Dhir R, Gollin SM et al (2006) Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 37:401–409
Di Vizio D, Sotgia F, Williams TM et al (2007) Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 6:1263–1268
Migita T, Ruiz S, Fornari A et al (2009) Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101:519–532
Wei S, Dunn TA, Isaacs WB et al (2008) GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 68:1387–1395
Varambally S, Laxman B, Mehra R et al (2008) Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 10:1285–1294
Wang W, Sun X, Epstein JI (2008) Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol 32:851–857
Kinoshita Y, Kuratsukuri K, Landas S et al (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30:628–636
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kristiansen, G. Immunhistochemische Algorithmen in der Prostatadiagnostik. Pathologe 30 (Suppl 2), 146–153 (2009). https://doi.org/10.1007/s00292-009-1230-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-009-1230-4